Tislelizumab with chemo and radiation before surgery for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with squamous cell carcinoma of the esophagus.
- Your cancer is advanced (stage T4) or has spread to lymph nodes that cannot be removed by surgery.
- You are at least 20 years old.
- You are in good enough health to have daily activities (ECOG 0 or 1).
- Your liver, kidney, and blood counts are within certain limits.
- You are willing to have surgery after chemo and radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests a new combination of short-course radiation, an immunotherapy drug (tislelizumab), and chemotherapy before surgery for esophageal cancer. It aims to shrink tumors and improve surgical outcomes.
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
This study tests whether giving radiation therapy based on how well the tumor responds to initial chemoimmunotherapy can improve outcomes for people with a certain type of esophageal cancer. The goal is to find a more personalized treatment approach that may be more effective and possibly reduce side effects.
This trial tests whether combining tislelizumab (an immunotherapy drug) with chemotherapy can shrink advanced esophageal cancer before surgery. The goal is to help patients whose tumors are too large or invasive to operate on initially.
This trial tests a combination of chemotherapy, immunotherapy, and chemoradiation before surgery for people with advanced esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.